ALBANY, N.Y. , Dec. 18, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, is scheduled to present at the 32 nd Annual J.P.

ALBANY, N.Y. , Dec. 12, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report its fiscal 2014 second quarter financial results

ALBANY, N.Y. , Dec. 11, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the appointment of John Soto as Chief Commercial Officer, a

ALBANY, N.Y. , Dec. 10, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced the Centers for Medicare and Medicaid Services (CMS) has created a new

Company Expects to Save $15 Million to $18 Million Over the Next Three Years

ALBANY, N.Y. , Nov. 20, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, is scheduled to participate in a Q&A session at the 25 th Annual Piper Jaffray

ALBANY, N.Y. , Nov. 4, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Joseph M. DeVivo , President and Chief Executive Officer,

CE Mark Covers Venous Drainage Cannula and Cardiopulmonary Bypass Circuit; Cannula Indicated for Removal of Fresh, Soft Thrombi or Emboli

Net sales of $83.6 million GAAP net loss of $0.01 per share; Non-GAAP adjusted net income of $0.04 per share; Non-GAAP adjusted net income excluding amortization of $0.12 per share Adjusted EBITDA of $11.3 million Operating cash flow of $7.3 million versus prior year $5.6 million cash use Company

ALBANY, N.Y. , Oct. 10, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced that it has signed a sole-source, three-year port product agreement

Multi-Center Study Investigates Whether BioFlo PICCs Are Associated With Reduced Catheter-Related Thrombosis

ALBANY, N.Y. , Sept. 24, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it amended its existing credit facilities and successfully

ALBANY, N.Y. , Sept. 23, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, and Interface Biologics Inc. (IBI), a privately-held commercial stage developer

ALBANY, N.Y. , Sept. 19, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report its fiscal 2014 first quarter financial results

Celerity System to be Showcased at AVA 2013

ALBANY, N.Y. , Aug. 28, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, is scheduled to present at the Stifel Nicolaus 2013 Healthcare Conference on

Multi-Center Study Focused on the Ablation of Prostate Cancer

ALBANY, N.Y. , Aug. 20, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced the U.S. Food and Drug Administration has granted 510(k) clearance to

Decision Expands Patient Access to Minimally Invasive Treatments Like the VenaCure EVLT System in the United Kingdom

ALBANY, N.Y. , Aug. 1, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, is scheduled to present at the 33 rd Annual Canaccord Growth Conference on